bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods from Gene Signatures Associated with Mouse Postnatal Hindbrain Neural Stem Cells and Medulloblastoma Cancer Stem Cells Identify Novel Molecular Mediators and Predict Human Medulloblastoma Molecular Classification
Authors: Corno Daniela , Pala Mauro , Cominelli Manuela , Cipelletti Barbara , Leto Ketty , Croci Laura , Barili Valeria , Brandalise Federico , Melzi Raffaella , Di Gregorio Alessandra , Sergi Lucia Sergi , Politi Letterio Salvatore , Piemonti Lorenzo , Bulfone Alessandro , Rossi Paola , Rossi Ferdinando , Consalez Gian Giacomo , Poliani Pietro Luigi , Galli Rossella
Published: April 2023

PDF file - 104K, Details on experimental and bioinformatics procedures.
Supplementary Figure 3 from Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrow–Derived Cells
Authors: Kuznetsov Hanna S. , Marsh Timothy , Markens Beth A. , Castaño Zafira , Greene-Colozzi April , Hay Samantha A. , Brown Victoria E. , Richardson Andrea L. , Signoretti Sabina , Battinelli Elisabeth M. , McAllister Sandra S.
Published: April 2023

PDF file - 166K, Efficiency of BMC transplantation and tissue recruitment of BMCs; effects of LBC environment on responding tumor cell CD24 enrichment and circulating platelet counts
Supplementary Table S3 from Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1
Authors: Laine Anni , Sihto Harri , Come Christophe , Rosenfeldt Mathias T. , Zwolinska Aleksandra , Niemelä Minna , Khanna Anchit , Chan Edward K. , Kähäri Veli-Matti , Kellokumpu-Lehtinen Pirkko-Liisa , Sansom Owen J. , Evan Gerard I. , Junttila Melissa R. , Ryan Kevin M. , Marine Jean-Christophe , Joensuu Heikki , Westermarck Jukka
Published: April 2023

Supplementary Table S3 PDF file - 64K, Sequences of siRNAS, RT-PCR primers and ChIP primers
Supplementary Figure 1 from Gene Signatures Associated with Mouse Postnatal Hindbrain Neural Stem Cells and Medulloblastoma Cancer Stem Cells Identify Novel Molecular Mediators and Predict Human Medulloblastoma Molecular Classification
Authors: Corno Daniela , Pala Mauro , Cominelli Manuela , Cipelletti Barbara , Leto Ketty , Croci Laura , Barili Valeria , Brandalise Federico , Melzi Raffaella , Di Gregorio Alessandra , Sergi Lucia Sergi , Politi Letterio Salvatore , Piemonti Lorenzo , Bulfone Alessandro , Rossi Paola , Rossi Ferdinando , Consalez Gian Giacomo , Poliani Pietro Luigi , Galli Rossella
Published: April 2023

PDF file - 132K, The gene signature containing the 297 genes differentially expressed between hindbrain- vs. forebrain-derived NSCs distinguishes the SHH molecular subgroup of human MBs
Supplementary Video 4 from Reversing Resistance to Vascular-Disrupting Agents by Blocking Late Mobilization of Circulating Endothelial Progenitor Cells
Authors: Taylor Melissa , Billiot Fanny , Marty Virginie , Rouffiac Valérie , Cohen Patrick , Tournay Elodie , Opolon Paule , Louache Fawzia , Vassal Gilles , Laplace-Builhé Corinne , Vielh Philippe , Soria Jean-Charles , Farace Françoise
Published: April 2023

AVI file - 189K
Interview with Dr. Gabra from The OPCML Tumor Suppressor Functions as a Cell Surface Repressor–Adaptor, Negatively Regulating Receptor Tyrosine Kinases in Epithelial Ovarian Cancer
Authors: McKie Arthur B. , Vaughan Sebastian , Zanini Elisa , Okon Imoh S. , Louis Louay , de Sousa Camila , Greene Mark I. , Wang Qiang , Agarwal Roshan , Shaposhnikov Dmitry , Wong Joshua L. C. , Gungor Hatice , Janczar Szymon , El-Bahrawy Mona , Lam Eric W-F. , Chayen Naomi E. , Gabra Hani
Published: April 2023

mp3 file (7.8 MB). In the February edition of the Cancer Discovery podcast, Executive Editor Mark Landis talks with Hani Gabra about his paper, which demonstrates that OPCML binds the extracellular domains of specific receptor tyrosine kinases to induce their endocytic internalization and proteasomal degradation.
Supplementary Tables 1-10 from microRNA Regulatory Network Inference Identifies miR-34a as a Novel Regulator of TGF-β Signaling in Glioblastoma
Authors: Genovese Giannicola , Ergun Ayla , Shukla Sachet A. , Campos Benito , Hanna Jason , Ghosh Papia , Quayle Steven N. , Rai Kunal , Colla Simona , Ying Haoqiang , Wu Chang-Jiun , Sarkar Sharmistha , Xiao Yonghong , Zhang Jianhua , Zhang Hailei , Kwong Lawrence , Dunn Katherine , Wiedemeyer Wolf Ruprecht , Brennan Cameron , Zheng Hongwu , Rimm David L. , Collins James J. , Chin Lynda
Published: April 2023

PDF file - 1.1MB, Supplementary Table 1: list of 290 TCGA samples used in the study. Supplementary Table 2: list of miR-mRNA edges identified by CLR. Supplementary Table 3: list of putative direct miR-mRNA edges in the network. Supplementary Table 4: miR-mRNA edges identified as unique to each of the 4 molecular subtypes. (A) Classical (B) Neural (C) Proneural (D) Mesenchymal. Supplementary Table 5: miR and mRNA nodes in regions of copy number aberration in the sub-network corresponding to the 8 discriminatory miRs. Supplementary Table 6: survival analysis results for the 8 discriminatory miRs. Supplementary Table 7: multivariate Cox regression analysis in the TCGA dataset and in the 4 molecular subclasses. Supplementary Table 8: patients' characteristics (validation cohort, n=220). Supplementary Table 9: AQUA values (raw data) for miR-34a expression in Glioblastoma TMAs (validation cohort). Supplementary Table 10: list of transcription factors enriched in the PN subtype
Figure S3 from Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of BrafV600E–Driven Lung Tumors
Authors: Strohecker Anne M. , Guo Jessie Yanxiang , Karsli-Uzunbas Gizem , Price Sandy M. , Chen Guanghua Jim , Mathew Robin , McMahon Martin , White Eileen
Published: April 2023

Figure S3 - PDF file 605K, Loss of ATG7 is associated with increased early tumorigenesis
Supplementary Figure S7 from Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Authors: Montero-Conde Cristina , Ruiz-Llorente Sergio , Dominguez Jose M. , Knauf Jeffrey A. , Viale Agnes , Sherman Eric J. , Ryder Mabel , Ghossein Ronald A. , Rosen Neal , Fagin James A.
Published: April 2023

Supplementary Figure S7 PDF file - 68K, Genetic knock-down or pharmacological inhibition of HER3 synergizes with PLX4032 and AZD6244, respectively, to inhibit growth of BRAF mutant thyroid cancer cells. A, SW1736 cells were treated with PLX4032 (0-2000 nM) with or without 1 �gM lapatinib or after stable expression of a shRNA to HER3. Indicated concentrations of PLX4032 and lapatinib were added at day 0 and day 3 and growth was measured 6 days after the first treatment. Points represent percent change (mean +/- SD) in cell count of triplicate wells compared to untreated cells. B, SW1736 cells were treated with 2 �gM PLX4032 or 100 nM AZD6244 and lysates collected at 1 and 72 h. Immunoblotting shows induction of pHER3 by both inhibitors. C, SW1736 and 8505C cells were treated with increasing concentrations of AZD6244 alone (open bars) or in combination with 1 �gM lapatinib (black). Cells were collected and counted after 4 days of treatment. Bars represent percent change (mean +/- SD) in cell counts of triplicate wells compared to untreated cells
Supplementary Tables 1-3 and Table A-1, Figure 1, Appendix and Information from The BATTLE Trial: Personalizing Therapy for Lung Cancer
Authors: Kim Edward S. , Herbst Roy S. , Wistuba Ignacio I. , Lee J. Jack , Blumenschein George R. , Tsao Anne , Stewart David J. , Hicks Marshall E. , Erasmus Jeremy , Gupta Sanjay , Alden Christine M. , Liu Suyu , Tang Ximing , Khuri Fadlo R. , Tran Hai T. , Johnson Bruce E. , Heymach John V. , Mao Li , Fossella Frank , Kies Merrill S. , Papadimitrakopoulou Vassiliki , Davis Suzanne E. , Lippman Scott M. , Hong Waun K.
Published: April 2023

Supplementary Tables 1-3 and Table A-1, Figure 1, Appendix and Information from The BATTLE Trial: Personalizing Therapy for Lung Cancer
Supplementary Figure S3 from Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Authors: Montero-Conde Cristina , Ruiz-Llorente Sergio , Dominguez Jose M. , Knauf Jeffrey A. , Viale Agnes , Sherman Eric J. , Ryder Mabel , Ghossein Ronald A. , Rosen Neal , Fagin James A.
Published: April 2023

Supplementary Figure S3 PDF file - 91K, Lack of pHER3 induction by PLX4032 in BRAF mutant colorectal cancer cell lines. A, western blots of colorectal carcinoma cells treated with 2 �gM PLX4032 for the indicated times. Immunoblots for pHER3 were imaged after prolonged exposure (contrast to Figure 2C). No induction of total or pHER3 was noted in any of the cell lines
Supplementary Table 1 from Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention
Authors: Jia Shidong , Gao Xueliang , Lee Sang Hyun , Maira Sauveur-Michel , Wu Xiaoqiu , Stack Edward C. , Signoretti Sabina , Loda Massimo , Zhao Jean J. , Roberts Thomas M.
Published: April 2023

Supplementary Table 1 PDF file - 98K, p53 somatic point mutations in PTEN-null CRPC
Supplementary Table 2 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Authors: Bjerke Lynn , Mackay Alan , Nandhabalan Meera , Burford Anna , Jury Alexa , Popov Sergey , Bax Dorine A. , Carvalho Diana , Taylor Kathryn R. , Vinci Maria , Bajrami Ilirjana , McGonnell Imelda M. , Lord Christopher J. , Reis Rui M. , Hargrave Darren , Ashworth Alan , Workman Paul , Jones Chris
Published: April 2023

XLSX file - 1310K, Differentially bound ChIP-Seq regions and genes in paediatric GBM cells.
Supplementary Table 1 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Authors: Bjerke Lynn , Mackay Alan , Nandhabalan Meera , Burford Anna , Jury Alexa , Popov Sergey , Bax Dorine A. , Carvalho Diana , Taylor Kathryn R. , Vinci Maria , Bajrami Ilirjana , McGonnell Imelda M. , Lord Christopher J. , Reis Rui M. , Hargrave Darren , Ashworth Alan , Workman Paul , Jones Chris
Published: April 2023

PDF file - 12611K, Datasets used for gene expression profiling analysis.
Supplementary Figures 1 - 13 from Histone H3.3 Mutations Drive Pediatric Glioblastoma through Upregulation of MYCN
Authors: Bjerke Lynn , Mackay Alan , Nandhabalan Meera , Burford Anna , Jury Alexa , Popov Sergey , Bax Dorine A. , Carvalho Diana , Taylor Kathryn R. , Vinci Maria , Bajrami Ilirjana , McGonnell Imelda M. , Lord Christopher J. , Reis Rui M. , Hargrave Darren , Ashworth Alan , Workman Paul , Jones Chris
Published: April 2023

PDF file - 495K, Collated supplementary figures. S1 - Expression of histone H3 methylation marks in paediatric glioma and normal cell lines. S2 - Further characterisation of KNS42 cells. S3 - H3K36me3 binding in H3F3A wild-type SF188 paediatric GBM cells. S4 -Spatio-temporal gene expression of H3F3A mutation-specific signatures in the human brain S5-S12 - Validation of differential H3K36me3 binding and expression of developmental transcription factors and genes associated with stem cell maintenance and pluripotency S13 - MYCN expression in G34V isogenic cells
Supplementary Figure 4 from Antagonism of Inhibitor of Apoptosis Proteins Increases Bone Metastasis via Unexpected Osteoclast Activation
Authors: Yang Chang , Davis Jennifer L. , Zeng Rong , Vora Paras , Su Xinming , Collins Lynne I. , Vangveravong Suwanna , Mach Robert H. , Piwnica-Worms David , Weilbaecher Katherine N. , Faccio Roberta , Veis Novack Deborah
Published: April 2023

PDF file - 382K,Western blot showing p100 to p52 processing in response to RANKL and BV6
Supplementary Table 5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Authors: Guagnano Vito , Kauffmann Audrey , Wöhrle Simon , Stamm Christelle , Ito Moriko , Barys Louise , Pornon Astrid , Yao Yao , Li Fang , Zhang Yun , Chen Zhi , Wilson Christopher J. , Bordas Vincent , Le Douget Mickaël , Gaither L. Alex , Borawski Jason , Monahan John E. , Venkatesan Kavitha , Brümmendorf Thomas , Thomas David M. , Garcia-Echeverria Carlos , Hofmann Francesco , Sellers William R. , Graus-Porta Diana
Published: April 2023

XML file - 56K, High throughput pharmacological screen of BGJ398 in 517 cancer cell lines
Supplementary Text from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
Authors: Yuan Huiling , Qin Fujun , Movassagh Mercedeh , Park Hong , Golden Wendy , Xie Zhongqiu , Zhang Peng , Sklar Jeffrey , Li Hui
Published: April 2023

- PDF file 167K, Supplementary methods, figures and tables
Supplementary Figures 1-5 from FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor
Authors: Guagnano Vito , Kauffmann Audrey , Wöhrle Simon , Stamm Christelle , Ito Moriko , Barys Louise , Pornon Astrid , Yao Yao , Li Fang , Zhang Yun , Chen Zhi , Wilson Christopher J. , Bordas Vincent , Le Douget Mickaël , Gaither L. Alex , Borawski Jason , Monahan John E. , Venkatesan Kavitha , Brümmendorf Thomas , Thomas David M. , Garcia-Echeverria Carlos , Hofmann Francesco , Sellers William R. , Graus-Porta Diana
Published: April 2023

PDF file - 1.4MB, Response to NVP-BGJ398; FGFR pathway modulation by NVP-BGJ398; NVP-BGJ398 - predictive features; FGFR2-c3 mRNA expression in cell lines and FGFR2 DNA copy number in tumors; FGF19 DNA copy number in CCLE cell lines and FGFR3 DNA copy number versus transcript expression in bladder cancer cell lines
Supplementary Fiures from A Chimeric RNA Characteristic of Rhabdomyosarcoma in Normal Myogenesis Process
Authors: Yuan Huiling , Qin Fujun , Movassagh Mercedeh , Park Hong , Golden Wendy , Xie Zhongqiu , Zhang Peng , Sklar Jeffrey , Li Hui
Published: April 2023

- PDF file 1635K, Additional evidence for the presence of PAX3-FOXO1 and absence of chromosomal translocation
Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
Authors: Durinck Steffen , Ho Christine , Wang Nicholas J. , Liao Wilson , Jakkula Lakshmi R. , Collisson Eric A. , Pons Jennifer , Chan Sai-Wing , Lam Ernest T. , Chu Catherine , Park Kyunghee , Hong Sung-woo , Hur Joe S. , Huh Nam , Neuhaus Isaac M. , Yu Siegrid S. , Grekin Roy C. , Mauro Theodora M. , Cleaver James E. , Kwok Pui-Yan , LeBoit Philip E. , Getz Gad , Cibulskis Kristian , Aster Jon C. , Huang Haiyan , Purdom Elizabeth , Li Jian , Bolund Lars , Arron Sarah T. , Gray Joe W. , Spellman Paul T. , Cho Raymond J.
Published: April 2023

Supplementary Table 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers
Authors: Durinck Steffen , Ho Christine , Wang Nicholas J. , Liao Wilson , Jakkula Lakshmi R. , Collisson Eric A. , Pons Jennifer , Chan Sai-Wing , Lam Ernest T. , Chu Catherine , Park Kyunghee , Hong Sung-woo , Hur Joe S. , Huh Nam , Neuhaus Isaac M. , Yu Siegrid S. , Grekin Roy C. , Mauro Theodora M. , Cleaver James E. , Kwok Pui-Yan , LeBoit Philip E. , Getz Gad , Cibulskis Kristian , Aster Jon C. , Huang Haiyan , Purdom Elizabeth , Li Jian , Bolund Lars , Arron Sarah T. , Gray Joe W. , Spellman Paul T. , Cho Raymond J.
Published: April 2023

Supplementary Figure Legends 1-4, Methods from Temporal Dissection of Tumorigenesis in Primary Cancers
Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
Authors: Durinck Steffen , Ho Christine , Wang Nicholas J. , Liao Wilson , Jakkula Lakshmi R. , Collisson Eric A. , Pons Jennifer , Chan Sai-Wing , Lam Ernest T. , Chu Catherine , Park Kyunghee , Hong Sung-woo , Hur Joe S. , Huh Nam , Neuhaus Isaac M. , Yu Siegrid S. , Grekin Roy C. , Mauro Theodora M. , Cleaver James E. , Kwok Pui-Yan , LeBoit Philip E. , Getz Gad , Cibulskis Kristian , Aster Jon C. , Huang Haiyan , Purdom Elizabeth , Li Jian , Bolund Lars , Arron Sarah T. , Gray Joe W. , Spellman Paul T. , Cho Raymond J.
Published: April 2023

Supplementary Figure 2 from Temporal Dissection of Tumorigenesis in Primary Cancers
Supplementary Observations from NOTCH Decoys That Selectively Block DLL/NOTCH or JAG/NOTCH Disrupt Angiogenesis by Unique Mechanisms to Inhibit Tumor Growth
Authors: Kangsamaksin Thaned , Murtomaki Aino , Kofler Natalie M. , Cuervo Henar , Chaudhri Reyhaan A. , Tattersall Ian W. , Rosenstiel Paul E. , Shawber Carrie J. , Kitajewski Jan
Published: April 2023

Supplementary Observations.
Supplementary Figure 4 from Autophagy Is Critical for Pancreatic Tumor Growth and Progression in Tumors with p53 Alterations
Authors: Yang Annan , Rajeshkumar N.V. , Wang Xiaoxu , Yabuuchi Shinichi , Alexander Brian M. , Chu Gerald C. , Von Hoff Daniel D. , Maitra Anirban , Kimmelman Alec C.
Published: April 2023

PDF file - 283KB, Western blot on tumor lines derived from primary tumors confirmed Atg5 status and also showed loss of p53.
Figure S5 from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
Authors: Mathew Lijoy K. , Lee Samuel S. , Skuli Nicolas , Rao Shilpa , Keith Brian , Nathanson Katherine L. , Lal Priti , Simon M. Celeste
Published: April 2023

PDF file 28K, miR-30c-2-3p, miR-30a-3p and HIF2? levels in stable UMRC2 cells
Figure S4 from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
Authors: Mathew Lijoy K. , Lee Samuel S. , Skuli Nicolas , Rao Shilpa , Keith Brian , Nathanson Katherine L. , Lal Priti , Simon M. Celeste
Published: April 2023

PDF file 53K, Cell proliferation modulated by miR-30c-2-3p in ccRCCs
Supplementary Figure 4 from Primary Melanoma of the CNS in Children Is Driven by Congenital Expression of Oncogenic NRAS in Melanocytes
Authors: Pedersen Malin , Küsters-Vandevelde Heidi V.N. , Viros Amaya , Groenen Patricia J.T.A. , Sanchez-Laorden Berta , Gilhuis Jacobus H. , van Engen-van Grunsven Ilse A. , Renier Willy , Schieving Jolanda , Niculescu-Duvaz Ion , Springer Caroline J. , Küsters Benno , Wesseling Pieter , Blokx Willeke A.M. , Marais Richard
Published: April 2023

Supplementary Figure 4 PDF file - 39K, Sequencing of RT-PCR amplified cDNA is presented to show that NRASG12D is expressed in the CNS tumors of our mice
Figure S2 from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
Authors: Mathew Lijoy K. , Lee Samuel S. , Skuli Nicolas , Rao Shilpa , Keith Brian , Nathanson Katherine L. , Lal Priti , Simon M. Celeste
Published: April 2023

PDF file 42K, miR-30c-2-3p and miR-30a-3p are not regulated by HIFs
Supplementary Methods, Table S1, Figures S1 - S8 from PRMT5 Is Required for Lymphomagenesis Triggered by Multiple Oncogenic Drivers
Authors: Li Yan , Chitnis Nilesh , Nakagawa Hiroshi , Kita Yoshiaki , Natsugoe Shoji , Yang Yi , Li Zihai , Wasik Mariusz , Klein-Szanto Andres J.P. , Rustgi Anil K. , Diehl J. Alan
Published: April 2023

Supplementary Table S1. T cell receptor (TCR) Vβ repertoire usage in CD3+CD4+ T cells from tumor-bearing and non tumor-bearing mice. Supplementary Figure S1. Pancytopenia in D1T286A-reconstituted mice, immnuphenotype of PRMT5-reconstituted mice and TCR clonality of D1T286A+PRMT5 mice. Supplementary Figure S2 Phenotype of the D1T286A+PRMT5 lymphoma and the D1T286A and PRMT5 triggered lymphoma is 100% transplantable. Supplementary Figure S3. PRMT5 is required for leukemia driven by MLL-AF9. Supplementary Figure S4. Cyclin D1T286A triggers T/B-cell lymphoma in p53 dependent way. Supplementary Figure S5. Confirmation of Cyclin D1T286A/PRMT5 expression and p53me2 antibody. Supplementary Figure S6. Cyclin D1T286A/CDK4 phosphorylation of MEP50 increases PRMT5-dependent methylation of p53. Supplementary Figure S7. Effect of PRMT5 and D1T286A on the Apaf1, Cdkn1a, Bax and Pmaip1 promoters. Supplementary Figure S8. PRMT5 and/or H4R3 are elevated in primary human cancers.
Supplementary Table S2 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Authors: Miao Benchun , Ji Zhenyu , Tan Li , Taylor Michael , Zhang Jianming , Choi Hwan Geun , Frederick Dennie T. , Kumar Raj , Wargo Jennifer A. , Flaherty Keith T. , Gray Nathanael S. , Tsao Hensin
Published: April 2023

Supplementary Table S2. Combination indices per method of Chou and Talalay.
Supplementary Figure Legends from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma
Authors: Miao Benchun , Ji Zhenyu , Tan Li , Taylor Michael , Zhang Jianming , Choi Hwan Geun , Frederick Dennie T. , Kumar Raj , Wargo Jennifer A. , Flaherty Keith T. , Gray Nathanael S. , Tsao Hensin
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 4 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
Authors: Grabiner Brian C. , Nardi Valentina , Birsoy Kıvanç , Possemato Richard , Shen Kuang , Sinha Sumi , Jordan Alexander , Beck Andrew H. , Sabatini David M.
Published: April 2023

PDF file 143K, mTOR mutants alter Deptor binding and nutrient deprivation, but not sensitivity to mTOR inhibitors
Supplementary Figures S1 - S8 from HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Authors: Kavuri Shyam M. , Jain Naveen , Galimi Francesco , Cottino Francesca , Leto Simonetta M. , Migliardi Giorgia , Searleman Adam C. , Shen Wei , Monsey John , Trusolino Livio , Jacobs Samuel A. , Bertotti Andrea , Bose Ron
Published: April 2023

Supplementary Figure S1. Drug sensitivity of HER2 or KRAS mutations in soft agar colony formation assay. Supplementary Figure S2. NCI-H508 cell xenograft growth curves. Supplementary Figure S3. Neratinib sensitivity of KRAS WT and KRAS mutant colorectal cancer lines. Supplementary Figure S4. HER2 mutant PDX's are cetuximab resistant. Supplementary Figure S5. Immunohistochemistry on PDX M122. Supplementary Figure S6. Immunohistochemistry on PDX M051. Supplementary Figure S7. HER2 L866M is an activating mutation that confers cetuximab resistance. Supplementary Figure S8. HER2 S310F is more sensitive to trastuzumab than HER2 L866M.
Supplementary Figures S1 - S8 from The Genetics of Splicing in Neuroblastoma
Authors: Chen Justin , Hackett Christopher S. , Zhang Shile , Song Young K. , Bell Robert J.A. , Molinaro Annette M. , Quigley David A. , Balmain Allan , Song Jun S. , Costello Joseph F. , Gustafson W. Clay , Van Dyke Terry , Kwok Pui-Yan , Khan Javed , Weiss William A.
Published: April 2023

Supplementary Figure S1. DDX26B and RBMX2 Influence Alternative Splicing. Supplementary Figure S2. Astn2 possesses a cis-sQTL. Supplementary Figure S3. SCNVs Identified by WGS. Supplementary Figure S4. Fubp1 RT-PCR From Parental Mouse Strains. Supplementary Figure S5. FUBP1 Expression Correlates with Survival in Two Neuroblastoma Datasets. Supplementary Figure S6. Total Set of Identified Unique Splicing Motifs. Supplementary Figure S7. Motifs with Matches to an RNA Binding database. Supplementary Figure S8. Recurrent Somatic Mutations Occur in Intronic Splicing Motifs in GBM.
Supplementary Figure Legends, Table Legends from The Genetics of Splicing in Neuroblastoma
Authors: Chen Justin , Hackett Christopher S. , Zhang Shile , Song Young K. , Bell Robert J.A. , Molinaro Annette M. , Quigley David A. , Balmain Allan , Song Jun S. , Costello Joseph F. , Gustafson W. Clay , Van Dyke Terry , Kwok Pui-Yan , Khan Javed , Weiss William A.
Published: April 2023

Supplementary Figure Legends, Table Legends
Supplementary Tables 1 - 5 from Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy
Authors: Ma Chao , Cheung Ann F. , Chodon Thinle , Koya Richard C. , Wu Zhongqi , Ng Charles , Avramis Earl , Cochran Alistair J. , Witte Owen N. , Baltimore David , Chmielowski Bartosz , Economou James S. , Comin-Anduix Begonya , Ribas Antoni , Heath James R.
Published: April 2023

PDF file - 131K, Protein and cell specificity studied, comparison of polyfunctional T cells and other cells.
Supplementary Table S4 from Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Authors: de Bruin Elza C. , Cowell Catherine , Warne Patricia H. , Jiang Ming , Saunders Rebecca E. , Melnick Mary Ann , Gettinger Scott , Walther Zenta , Wurtz Anna , Heynen Guus J. , Heideman Daniëlle A.M. , Gómez-Román Javier , García-Castaño Almudena , Gong Yixuan , Ladanyi Marc , Varmus Harold , Bernards René , Smit Egbert F. , Politi Katerina , Downward Julian
Published: April 2023

PDF file 108K, Table S4. Clinical characteristics of human lung adenocarcinoma samples
Supplementary Figures 1-7 from Reduced NF1 Expression Confers Resistance to EGFR Inhibition in Lung Cancer
Authors: de Bruin Elza C. , Cowell Catherine , Warne Patricia H. , Jiang Ming , Saunders Rebecca E. , Melnick Mary Ann , Gettinger Scott , Walther Zenta , Wurtz Anna , Heynen Guus J. , Heideman Daniëlle A.M. , Gómez-Román Javier , García-Castaño Almudena , Gong Yixuan , Ladanyi Marc , Varmus Harold , Bernards René , Smit Egbert F. , Politi Katerina , Downward Julian
Published: April 2023

PDF file 415K, Supplementary Figures 1-7. Figure S1, related to Figure 1. Genome-wide siRNA screen identifies determinants of resistance to erlotinib treatment. Figure S2, related to Figure 2. Reduced Nf1 expression in erlotinib-resistant EGFR-driven lung tumors. Figure S3, related to Figure 3. NF1 silencing confers resistance of lung adenocarcinoma cells to erlotinib. Figure S4, related to Figure 4. : NF1 downregulation activates MAPK pathway signaling. Figure S5, related to Figure 5. Low neurofibromin expressing cells respond to erlotinib when combined with MEK inhibition. Figure S6, related to Figure 6. Erlotinib-resistant murine EGFRL858R lung adenocarcinomas respond to combined EGFR and MEK inhibition. Figure S7, related to Figure 7. Reduced NF1 expression in erlotinib-resistant human NSCLC samples
Supplementary Figures S1-S11 from Pten-Null Tumors Cohabiting the Same Lung Display Differential AKT Activation and Sensitivity to Dietary Restriction
Authors: Curry Natasha L. , Mino-Kenudson Mari , Oliver Trudy G. , Yilmaz Ömer H. , Yilmaz Vedat O. , Moon Jade Y. , Jacks Tyler , Sabatini David M. , Kalaany Nada Y.
Published: April 2023

Supplementary Figures S1-S11 - PDF file 1955K, The Supplementary figures (Figs. S1-S11) provide additional characterization of the KPTEN, Kp53 and KPTENp53 mouse models of lung cancer, the alveolar and bronchiolar tumors they harbor, and the cells derived from these tumors
Supplementary Figure S6 from Intratumoral Heterogeneity in a Trp53-Null Mouse Model of Human Breast Cancer
Authors: Zhang Mei , Tsimelzon Anna , Chang Chi-Hsuan , Fan Cheng , Wolff Andrew , Perou Charles M. , Hilsenbeck Susan G. , Rosen Jeffrey M.
Published: April 2023

Supplementary Figure S6. Co-transplantation of the fluorescence labeled cells showed that a majority of the cells were generated from the TIC subpopulation.
Supplementary Figure S5 from Intratumoral Heterogeneity in a Trp53-Null Mouse Model of Human Breast Cancer
Authors: Zhang Mei , Tsimelzon Anna , Chang Chi-Hsuan , Fan Cheng , Wolff Andrew , Perou Charles M. , Hilsenbeck Susan G. , Rosen Jeffrey M.
Published: April 2023

Supplementary Figure S5. Blockade of IL6 signaling with shRNA in the niche cells reduced the self-renewal of the TICs.
Supplementary Figure 6 from Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Authors: Herrera-Abreu Maria Teresa , Pearson Alex , Campbell James , Shnyder Steve D. , Knowles Margaret A. , Ashworth Alan , Turner Nicholas C.
Published: April 2023

Supplementary Figure 6 - PDF file 123K, Mouse weights from xenograft experiments
Supplementary Figure 5 from Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer
Authors: Herrera-Abreu Maria Teresa , Pearson Alex , Campbell James , Shnyder Steve D. , Knowles Margaret A. , Ashworth Alan , Turner Nicholas C.
Published: April 2023

Supplementary Figure 5 - PDF file 243K, Analysis of FGFR3 mRNA and protein in 97-7 cells
Supplementary Figure 4 from NSD3–NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
Authors: French Christopher A. , Rahman Shaila , Walsh Erica M. , Kühnle Simone , Grayson Adlai R. , Lemieux Madeleine E. , Grunfeld Noam , Rubin Brian P. , Antonescu Cristina R. , Zhang Songlin , Venkatramani Rajkumar , Dal Cin Paola , Howley Peter M.
Published: April 2023

PDF file - 304KB, Supplementary Fig. S4. Among several ET-interacting proteins, only NSD3 is required for the blockade of differentiation in NMC. (A) Quantitative RT-PCR of NSD3, JMJD6, GLTSCR1, and ATAD5 levels 24 h following transfection of siRNAs. (B) Immunoblots of TC-797 lysates 120h following transfection with siRNAs.
Figure S5 from A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Authors: Elhammali Adnan , Ippolito Joseph E. , Collins Lynne , Crowley Jan , Marasa Jayne , Piwnica-Worms David
Published: April 2023

PDF file 43K, Effects of glutaminase (GLS1) inhibition on 3-phosphoglycerate levels in HT1080 cells. Quantification of 3-phosphoglycerate levels using GC-MS in HT1080 cells treated with DMSO, 300 microM Zaprinast, or 10 μM BPTES. Values were normalized first to total protein and then to DMSO treatment group to obtain relative metabolite levels (n=4, error bars represent S.D.)
Figure S4 from A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Authors: Elhammali Adnan , Ippolito Joseph E. , Collins Lynne , Crowley Jan , Marasa Jayne , Piwnica-Worms David
Published: April 2023

PDF file 132K, Effect of Zaprinast on histone methylatio Immortalized NHA cells were transduced with vector, wild type IDH1, or IDH1 R132H plasmids and treated with vehicle or 300 microM Zaprinast. Histone extraction was then performed. Western blot was performed to assess the levels of histone lysine residues H3K9Me2 (A) and H3K9Me3 (B) (top) with band quantification (bottom)
Supplementary Figures S1- S10 from Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer
Authors: Liu Yan , Marks Kevin , Cowley Glenn S. , Carretero Julian , Liu Qingsong , Nieland Thomas J.F. , Xu Chunxiao , Cohoon Travis J. , Gao Peng , Zhang Yong , Chen Zhao , Altabef Abigail B. , Tchaicha Jeremy H. , Wang Xiaoxu , Choe Sung , Driggers Edward M. , Zhang Jianming , Bailey Sean T. , Sharpless Norman E. , Hayes D. Neil , Patel Nirali M. , Janne Pasi A. , Bardeesy Nabeel , Engelman Jeffrey A. , Manning Brendan D. , Shaw Reuben J. , Asara John M. , Scully Ralph , Kimmelman Alec , Byers Lauren A. , Gibbons Don L. , Wistuba Ignacio I. , Heymach John V. , Kwiatkowski David J. , Kim William Y. , Kung Andrew L. , Gray Nathanael S. , Root David E. , Cantley Lewis C. , Wong Kwok-Kin
Published: April 2023

Supplementary Figure S1. Generation of GEMM-derived cell lines. Supplementary Figure S2. QPCR and Western blot analyses of DTYMK expression in 634 cells upon indicated shDtymks transduction. Supplementary Figure S3. Lkb1-wt 634 and Lkb1-null t4 cells transduced with shGFP, shDtymk-1 or shDtymk-3 and then cultured with or without additional 100 microM dTTP in medium for 4 days. Supplementary Figure S4. Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines (A) and human LKB1-wt (H358 and Calu-1) and LKB1-deficient H2122 and A549) NSCLC cell lines (B) were treated with CHEK1 inhibitors, AZD7762 and CHIR124, for the indicated dose and time, and then lysed for Western blot analysis of gammaH2AX. Supplementary Figure S5. Immunohistochemical analyses assessing gammaH2AZ. Supplementary Figure S6. QPCR and Western blot analyses of DTYMK expression in LKB1-wt Calu-1 NSCLC cells. Supplementary Figure S7. A schematic model is proposed based on our current data. Supplementary Figure S8. QPCR analyses of Dtymk (A) and Chek1 (B) transcript levels in Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines. Supplementary Figure S9. QPCR analysis of TK1 expression in 634 cells upon the indicated shTK1 transduction for 3 days. Supplementary Figure S10. Gene expression levels of DTYMK in normal lung vs. lung adenocarcinoma from the Oncomine Cancer Microarray database.
Supplementary Figure S6 from Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression
Authors: Wang Yufang , Velho Sérgia , Vakiani Efsevia , Peng Shouyong , Bass Adam J. , Chu Gerald C. , Gierut Jessica , Bugni James M. , Der Channing J. , Philips Mark , Solit David B. , Haigis Kevin M.
Published: April 2023

Supplementary Figure S6 PDF file 117K, Additional data concerning the relationship between mutant N-Ras and Stat3.
Supplementary Table 2 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Authors: Zill Oliver A. , Greene Claire , Sebisanovic Dragan , Siew Lai Mun , Leng Jim , Vu Mary , Hendifar Andrew E. , Wang Zhen , Atreya Chloe E. , Kelley Robin K. , Van Loon Katherine , Ko Andrew H. , Tempero Margaret A. , Bivona Trever G. , Munster Pamela N. , Talasaz AmirAli , Collisson Eric A.
Published: April 2023

Complete patient-level and mutation-level concordance information, mutation identities, and monitoring status for each patient in study.
Supplementary Table 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Authors: Zill Oliver A. , Greene Claire , Sebisanovic Dragan , Siew Lai Mun , Leng Jim , Vu Mary , Hendifar Andrew E. , Wang Zhen , Atreya Chloe E. , Kelley Robin K. , Van Loon Katherine , Ko Andrew H. , Tempero Margaret A. , Bivona Trever G. , Munster Pamela N. , Talasaz AmirAli , Collisson Eric A.
Published: April 2023

Characteristics of the 26 patients in study.
Supplementary Figure S4 from Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression
Authors: Wang Yufang , Velho Sérgia , Vakiani Efsevia , Peng Shouyong , Bass Adam J. , Chu Gerald C. , Gierut Jessica , Bugni James M. , Der Channing J. , Philips Mark , Solit David B. , Haigis Kevin M.
Published: April 2023

Supplementary Figure S4 PDF file 80K, Data related to the characterization of cell lines expressing mutant N-Ras. In addition, examples of quantitative western blots are shown
Supplementary Figure 1 from Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Authors: Zill Oliver A. , Greene Claire , Sebisanovic Dragan , Siew Lai Mun , Leng Jim , Vu Mary , Hendifar Andrew E. , Wang Zhen , Atreya Chloe E. , Kelley Robin K. , Van Loon Katherine , Ko Andrew H. , Tempero Margaret A. , Bivona Trever G. , Munster Pamela N. , Talasaz AmirAli , Collisson Eric A.
Published: April 2023

Comparisons of CA 19-9 concentration and cfDNA mutant allele fractions in plasma. (A-E) cfDNA mutant allele fractions ("cfDNA percentage") versus CA 19-9 units per milliliter (U/mL) were determined at similar times for five patients with three or more serial blood draws. cfDNA percentage represents the mutant allele fraction of the most abundant cfDNA mutation, as determined at time zero, for each patient. (F) cfDNA mutant allele fractions and CA 19-9 marker measurements for patient 56 over the course of four time points while on therapy (gemcitabine nab-paclitaxel). Note that draw number 1 occurred 17 days after diagnosis.
Supplementary Figure 3 from Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
Authors: Sawyer Sarah L. , Tian Lei , Kähkönen Marketta , Schwartzentruber Jeremy , Kircher Martin , Majewski Jacek , Dyment David A. , Innes A. Micheil , Boycott Kym M. , Moreau Lisa A. , Moilanen Jukka S. , Greenberg Roger A.
Published: April 2023

Supplementary Figure 3. BRCA1 mutations result in compromised DNA damage repair.
Supplementary Figure S1 from Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression
Authors: Wang Yufang , Velho Sérgia , Vakiani Efsevia , Peng Shouyong , Bass Adam J. , Chu Gerald C. , Gierut Jessica , Bugni James M. , Der Channing J. , Philips Mark , Solit David B. , Haigis Kevin M.
Published: April 2023

Supplementary Figure S1 PDF file 160K, Additional data relating to the inflammatory phenotypes of WT and N-Ras mutant animals
Supplementary Figure 1 from Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
Authors: Sawyer Sarah L. , Tian Lei , Kähkönen Marketta , Schwartzentruber Jeremy , Kircher Martin , Majewski Jacek , Dyment David A. , Innes A. Micheil , Boycott Kym M. , Moreau Lisa A. , Moilanen Jukka S. , Greenberg Roger A.
Published: April 2023

Supplementary Figure 1. BRCA1 mutations lead to impaired MMC induced DNA damage signaling.
Supplementary Methods from Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma
Authors: He Lei , Torres-Lockhart Kristine , Forster Nicole , Ramakrishnan Saranya , Greninger Patricia , Garnett Mathew J. , McDermott Ultan , Rothenberg Stephen M. , Benes Cyril H. , Ellisen Leif W.
Published: April 2023

Supplementary Methods PDF file 68K, Ancillary methods not included in main text
Supplementary Figure 5 from Mcl-1 and FBW7 Control a Dominant Survival Pathway Underlying HDAC and Bcl-2 Inhibitor Synergy in Squamous Cell Carcinoma
Authors: He Lei , Torres-Lockhart Kristine , Forster Nicole , Ramakrishnan Saranya , Greninger Patricia , Garnett Mathew J. , McDermott Ultan , Rothenberg Stephen M. , Benes Cyril H. , Ellisen Leif W.
Published: April 2023

Supplementary Figure 5 PDF file 130K, Organization and function of Bcl-2 family members are recapitulated in primary HNSCC
Supplementary Table 2 from Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance
Authors: Karsli-Uzunbas Gizem , Guo Jessie Yanxiang , Price Sandy , Teng Xin , Laddha Saurabh V , Khor Sinan , Kalaany Nada Y. , Jacks Tyler , Chan Chang S. , Rabinowitz Joshua D. , White Eileen
Published: April 2023

PDF file - 116KB, Differential expression analysis for significant biological processes by GO term DAVID Analysis for muscle tissues during fasting.
Supplementary Data from Autophagy Is Required for Glucose Homeostasis and Lung Tumor Maintenance
Authors: Karsli-Uzunbas Gizem , Guo Jessie Yanxiang , Price Sandy , Teng Xin , Laddha Saurabh V , Khor Sinan , Kalaany Nada Y. , Jacks Tyler , Chan Chang S. , Rabinowitz Joshua D. , White Eileen
Published: April 2023

PDF file - 3190KB, Supplementary Figures (S1-S6) provide additional characterization about effects of systemic autophagy ablation in normal adult tissues and tumors. Supplementary Methods supply detailed information of experiments.
Supplementary Data Figure 1 from Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets
Authors: Balko Justin M. , Giltnane Jennifer M. , Wang Kai , Schwarz Luis J. , Young Christian D. , Cook Rebecca S. , Owens Phillip , Sanders Melinda E. , Kuba Maria G. , Sánchez Violeta , Kurupi Richard , Moore Preston D. , Pinto Joseph A. , Doimi Franco D. , Gómez Henry , Horiuchi Dai , Goga Andrei , Lehmann Brian D. , Bauer Joshua A. , Pietenpol Jennifer A. , Ross Jeffrey S. , Palmer Gary A. , Yelensky Roman , Cronin Maureen , Miller Vincent A. , Stephens Phillip J. , Arteaga Carlos L.
Published: April 2023

PDF file 45K, Association of high Ki67 with basal-like status
Supplementary Figures from MAX Inactivation in Small Cell Lung Cancer Disrupts MYC–SWI/SNF Programs and Is Synthetic Lethal with BRG1
Authors: Romero Octavio A. , Torres-Diz Manuel , Pros Eva , Savola Suvi , Gomez Antonio , Moran Sebastian , Saez Carmen , Iwakawa Reika , Villanueva Alberto , Montuenga Luis M. , Kohno Takashi , Yokota Jun , Sanchez-Cespedes Montse
Published: April 2023

PDF file 422K, Fig. S1. Radio charts of the multiplex ligation-dependent probe amplification (MLPA), depicting intragenic deletions at the indicated lung cancer cell lines and lung primary tumor. The five exons of the MAX gene and the names and the relative location of the different probes used in the MLPA are also shown. The ratio charts depicting a the analysis of a normal DNA, an intragenic deletion of exons from 3 to 5 for the Lu134 cell line and deletion of the entire coding region for the Lu165 cell line are included. The radio chart for the tumorgraft from the same individual as the Lu134 cells is also depicted, ruling out the possibility of it being a cellculture artifact. Fig. S2. A, Cell proliferation, measured using MTT assays, was significantly greater in the cells carrying the empty vector (? control cells) than in those expressing ectopic MAX, from the parental H1417 cells. Lines represent the number of viable cells relative to the total number of cells at 0 h. Error bars, standard deviation *p<0.001. B, Western blot of total lysates of MAX in H1299tr-BRG1wt and H1299tr-BRG1mut cells, treated with (1 ng/μl) to allow BRG1 expression, depicts the ectopic expression of MAX in a hormone-free (HF) environment, or in the presence of glucocorticoids (GC) at the indicated concentrations. In the left panel, cells transfected with the 5'UTR-MAX constructs exhibit decreased levels of ectopic MAX in the BRG1mut cells compared with BRG1wt cells. On the right, cells transfected with the MAX construct lacking 5'UTR show similar levels of ectopic MAX regardless of the status of BRG1. C, Western blots illustrate the reduction of MAX upon depletion of BRG1 in the indicated lung cancer cells carrying amplification of MYC in an HF environment and at the indicated hours after treatment with GC (5 μM). TUBULIN is included as a loading control. Fig. S3. Enriched gene ontology (GO) classifications (p<0.05 for all categories shown) among genes up-regulated in the MAX gene-expression profile (from Table S2). Enrichment (represented by several GO categories) is significant for genes annotated as being involved in neural development and in glucose/carbohydrate metabolism
Supplementary Table 1 from Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth
Authors: Ran Leili , Sirota Inna , Cao Zhen , Murphy Devan , Chen Yuedan , Shukla Shipra , Xie Yuanyuan , Kaufmann Michael C. , Gao Dong , Zhu Sinan , Rossi Ferdinando , Wongvipat John , Taguchi Takahiro , Tap William D. , Mellinghoff Ingo K. , Besmer Peter , Antonescu Cristina R. , Chen Yu , Chi Ping
Published: April 2023

Supplementary Table 1: Differentially expressed genes (p<0.05, fold change >1.5) between oil and tamoxifen treated tumors to conditionally ablate Etv1.
Supplementary Figures 1 - 6 from Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth
Authors: Ran Leili , Sirota Inna , Cao Zhen , Murphy Devan , Chen Yuedan , Shukla Shipra , Xie Yuanyuan , Kaufmann Michael C. , Gao Dong , Zhu Sinan , Rossi Ferdinando , Wongvipat John , Taguchi Takahiro , Tap William D. , Mellinghoff Ingo K. , Besmer Peter , Antonescu Cristina R. , Chen Yu , Chi Ping
Published: April 2023

Supplementary Figure 1: Etv1 is required for intramuscular and myenteric ICC development. Supplementary Figure 2: Etv1 ablation with tamoxifen decreases Etv1 and Kit expression in Kit^delta558/+;Etv1^flox/flox;Rosa26^CreERT2/CreERT2 mice. Supplementary Figure 3: Etv1 positively regulates Kit expression in murine stomach. Supplementary Figure 4: ETV1 regulates KIT expression in GIST48 cells. Supplementary Figure 5: MAP kinase pathway inhibition decreases ETV1 target gene expression. Supplementary Figure 6: Dual lineage inhibition inhibits tumor initiation in vivo.
Supplementary Figure 1 from A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer
Authors: Stegeman Shane , Amankwah Ernest , Klein Kerenaftali , O'Mara Tracy A. , Kim Donghwa , Lin Hui-Yi , Permuth-Wey Jennifer , Sellers Thomas A. , Srinivasan Srilakshmi , Eeles Rosalind , Easton Doug , Kote-Jarai Zsofia , Amin Al Olama Ali , Benlloch Sara , Muir Kenneth , Giles Graham G. , Wiklund Fredrik , Gronberg Henrik , Haiman Christopher A. , Schleutker Johanna , Nordestgaard Børge G. , Travis Ruth C. , Neal David , Pharoah Paul , Khaw Kay-Tee , Stanford Janet L. , Blot William J. , Thibodeau Stephen , Maier Christiane , Kibel Adam S. , Cybulski Cezary , Cannon-Albright Lisa , Brenner Hermann , Kaneva Radka , Teixeira Manuel R. , Spurdle Amanda B. , Clements Judith A. , Park Jong Y. , Batra Jyotsna
Published: April 2023

Supplementary Figure 1. Forest Plot (Fixed effects model) of the 22 prostate cancer risk associated miRSNPs.
Supplementary Figure 1 from Active CREB1 Promotes a Malignant TGFβ2 Autocrine Loop in Glioblastoma
Authors: Rodón Laura , Gonzàlez-Juncà Alba , del Mar Inda María , Sala-Hojman Ada , Martínez-Sáez Elena , Seoane Joan
Published: April 2023

A graph showing the correlation of p-SMAD2 and p-CREB in GBM patients.
Supplementary Figure 2 from Canonical Wnt/β-catenin Signaling Drives Human Schwann Cell Transformation, Progression, and Tumor Maintenance
Authors: Watson Adrienne L. , Rahrmann Eric P. , Moriarity Branden S. , Choi Kwangmin , Conboy Caitlin B. , Greeley Andrew D. , Halfond Amanda L. , Anderson Leah K. , Wahl Brian R. , Keng Vincent W. , Rizzardi Anthony E. , Forster Colleen L. , Collins Margaret H. , Sarver Aaron L. , Wallace Margaret R. , Schmechel Stephen C. , Ratner Nancy , Largaespada David A.
Published: April 2023

Supplementary Figure 2 - PDF file 109K, Overexpression of activated β-catenin and knockdown of AXIN1 or GSK3B results in increased Wnt signaling and an induction of oncogenic properties in immortalized human Schwann cells
Supplementary Figures S1 - S6 from Pancreatic Cancer Metastases Harbor Evidence of Polyclonality
Authors: Maddipati Ravikanth , Stanger Ben Z.
Published: April 2023

Supplementary Figure S1. Characterization of the KPCX mouse model of pancreatic cancer. Supplementary Figure S2. Polyclonal cell clusters in peritoneal and diaphragm metastases are spaced widely apart. Supplementary Figure S3. Derivation of 458d cells for assessing the origins of polyclonal metastases. Supplementary Figure S4. Distribution of lung and liver metastases according to size. Supplementary Figure S5. Changes in clonal representation with growth of liver metastases. Supplementary Figure S6. Lung metastatic burden following single and cluster injections.
Supplementary Figure S3 from Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Authors: Miller Miles A. , Oudin Madeleine J. , Sullivan Ryan J. , Wang Stephanie J. , Meyer Aaron S. , Im Hyungsoon , Frederick Dennie T. , Tadros Jenny , Griffith Linda G. , Lee Hakho , Weissleder Ralph , Flaherty Keith T. , Gertler Frank B. , Lauffenburger Douglas A.
Published: April 2023

Supplementary Figure 3. Corresponds to Fig. 3C, showing U0126 and PD325901 elicit AXL upregulation to a degree that correlates with AXLi/MEKi synergy across a panel of cell lines.
Supplementary Figure Legends from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
Authors: Xie Huafeng , Peng Cong , Huang Jialiang , Li Bin E. , Kim Woojin , Smith Elenoe C. , Fujiwara Yuko , Qi Jun , Cheloni Giulia , Das Partha P. , Nguyen Minh , Li Shaoguang , Bradner James E. , Orkin Stuart H.
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 5 from Chronic Myelogenous Leukemia– Initiating Cells Require Polycomb Group Protein EZH2
Authors: Xie Huafeng , Peng Cong , Huang Jialiang , Li Bin E. , Kim Woojin , Smith Elenoe C. , Fujiwara Yuko , Qi Jun , Cheloni Giulia , Das Partha P. , Nguyen Minh , Li Shaoguang , Bradner James E. , Orkin Stuart H.
Published: April 2023

In vitro validation of Ezh2 gRNA and its impact on CML.